A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II) [PDF]
Caroline M. Apovian +7 more
openalex +1 more source
Neuroendocrinology meets addiction: Emerging pharmacotherapies on the horizon
Abstract Alcohol and other substance use disorders (ASUDs) are prevalent and major contributors to global morbidity and mortality. Their impact extends beyond the individual, imposing significant burdens on families, communities, healthcare systems, and society at large.
Anna Loften +3 more
wiley +1 more source
Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials [PDF]
David P. King +8 more
openalex +1 more source
Polymorphic Variants of Cytochrome P450 2B6 (CYP2B6.4–CYP2B6.9) Exhibit Altered Rates of Metabolism for Bupropion and Efavirenz: A Charge-Reversal Mutation in the K139E Variant (CYP2B6.8) Impairs Formation of a Functional Cytochrome P450-Reductase Complex [PDF]
Haoming Zhang +5 more
openalex +1 more source
Comparison of Glucose Control Profile in Patients With Depression and Type 2 Diabetes Receiving Bupropion or Venlafaxine: A Randomized Controlled Clinical Trial [PDF]
Mohammad Ali Bayani +3 more
openalex +1 more source
Hypomanic Switch Induced by Dextromethorphan-Bupropion Combination: A Case Report. [PDF]
Aggarwal M, Singh J, Udey B.
europepmc +1 more source
S. Nissen +7 more
semanticscholar +1 more source
Sex-stratified pharmacovigilance of gastrointestinal events associated with first-line smoking-cessation medicines: Insights from the FAERS database. [PDF]
Sun H, Chen J, Wu X, Wang Z.
europepmc +1 more source
Varenicline and Bupropion for Long-Term Smoking Cessation (the MATCH Study): Protocol for a Real-World, Pragmatic, Randomized Controlled Trial [PDF]
Laurie Zawertailo +5 more
openalex +1 more source

